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ABSTRACT
Pluripotent stem cells (PSCs) have the potential to pro-
duce any types of cells from all three basic germ layers
and the capacity to self-renew and proliferate indeﬁnitely
in vitro. The two main types of PSCs, embryonic stem
cells (ESCs) and induced pluripotent stem cells (iPSCs),
share common features suchas colonymorphology, high
expression of Oct4 and Nanog, and strong alkaline
phosphatase activity. In recent years, increasing evi-
dences suggest that telomere length represents another
important internal factor in maintaining stem cell pluri-
potency. Telomere length homeostasis and its structural
integrity help to protect chromosome ends from recom-
bination, end fusion, and DNA damage responses,
ensuring the divisional ability of mammalian cells. PSCs
generally exhibit high telomerase activity to maintain
their extremely long and stable telomeres, and emerging
data indicate the alternative lengthening of telomeres
(ALT) pathway may play an important role in telomere
functions too. Such characteristics are likely key to their
abilities to differentiate into diverse cell types in vivo. In
this review,wewill focuson the function and regulation of
telomeres in ESCs and iPSCs, thereby shedding light on
the importance of telomere length to pluripotency and the
mechanisms that regulate telomeres in PSCs.
KEYWORDS telomere, pluripotent stem cells, alternative
lengthening of telomeres (ALT), regulators
TELOMERES
Telomeres are hexametric repeats of (TTAGGG)n at the
chromosomal ends in mammalian cells. During the process
of DNA synthesis and cell division, telomeres are shortened
as a result of the incomplete replication of linear chromo-
somes, which is called “end-replication problem”. Telomere
attrition, which can cause chromosome recombination, end-
to-end fusion, DNA damage, and genome instability, repre-
sents one of the nine hallmarks of aging (Lopez-Otin et al.,
2013). Many pieces of evidence, including studies of telo-
merase null mouse models and diseases with premature
aging phenotypes such as dyskeratosis congenita (DC),
support the notion that telomere shortening is rate limiting for
mammalian lifespan and age-related diseases (Blasco et al.,
1997; Herrera et al., 1999; Mason et al., 2005).
Usually, telomere length is maintained by the telomerase,
containing the reverse transcriptase TERT and the RNA
template TERC, as well as associating proteins such as the
ribonucleoprotein dyskerin (DKC1) (Cohen et al., 2007).
Telomerase is responsible for the de novo telomere exten-
sion, to prevent telomere exhaustion after multiple rounds of
cell division (Greider and Blackburn, 1985, 1989). In addi-
tion, the telomere region is bound by a six-protein complex
called shelterin/telosome, containing TRF1, TRF2, TPP1,
POT1, TIN2 and RAP1, which is crucial for maintaining the
structure and function of telomeres (de Lange, 2005; Liu
et al., 2004; Xin et al., 2008).
In most cases, the telomerase is only activated in stem
cells, germ cells, certain white blood cells, and cancers. In a
signiﬁcant number of cases, however, telomeres can be
maintained without the telomerase, through possible mech-
anisms such as homologous recombination, which has been
termed alternative lengthening of telomeres (ALT). ALT has
been found to occur in about 10%–15% cancers and is often
characterized by co-localization of telomeres with the pro-
myelocytic leukemia (PML) bodies (known as ALT-associ-
ated PML bodies (APBs)), exceedingly heterogeneous
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telomere length, extra-chromosomal DNA circles, and high
frequencies of telomere sister chromatid exchange (T-SCE)
(Cesare and Reddel, 2010; Chung et al., 2012). ALT tends to
occur in tumors such as osteosarcoma and soft tissue sar-
comas derived from mesenchymal or neuroepithelial origin
(Cesare and Reddel, 2010; Henson et al., 2005; Scheel
et al., 2001). Interestingly, it was found that ALT and telo-
merase pathway could coexist in human cells under certain
circumstances (Cerone et al., 2001). By using a telomere-
tagged transgenic mouse strain, ALT was recently found to
exist in normal mouse somatic cells, but not in the germline
(Neumann et al., 2013). Furthermore, it was found that dur-
ing the early embryo cleavage stage, telomeres are also
lengthened by an ALT-like mechanism (Liu et al., 2007).
Increasing evidences indicate that telomeres are tightly
linked to epigenetic regulation. Many heterochromatin fea-
tures can be found in mammalian telomeric or subtelomeric
domains, such as trimethylation of H3K9 and H4K20 (Gar-
cia-Cao et al., 2004; Gonzalo et al., 2005), HP1 enrichment
(Lachner et al., 2001), low levels of acetylated H3 and H4
(Benetti et al., 2007a), and DNA hypermethylation in subt-
elomeric region (Gonzalo et al., 2006). These “silenced”
features in the nucleosome help to maintain a compressed
chromatin structure and telomere length homeostasis.
PLURIPOTENT STEM CELLS
Pluripotent stem cells, including the well-studied ESCs and
emerging iPSCs, promise great potential applications in the
medical and drug ﬁeld. ESCs were ﬁrst isolated from the
mouse inner cell mass (ICM) of blastocysts in 1981 (Evans
and Kaufman, 1981; Martin, 1981). In recent years, ESCs
can also be derived from somatic cell nuclear transfer
embryos (ntESCs), parthenogenetic embryos (pESCs), and
androgenetic embryos (aESCs). In 2006, the Yamanaka
group successfully obtained induced pluripotent stem cells
(iPSCs) by introducing four transcriptional factors into mouse
as well as human somatic cells (Takahashi et al., 2007;
Takahashi and Yamanaka, 2006). More detailed studies
have found that gene expression patterns, epigenetic states,
and telomere length status appeared to have been reversed
in this reprogramming process (Buganim et al., 2012; Marion
et al., 2009; Papp and Plath, 2013). iPSCs resemble ESCs
in multiple molecular markers as well as in producing all-
iPSC mice by tetraploid complementation technique (Kang
et al., 2009; Maherali et al., 2007; Mikkelsen et al., 2008;
Takahashi and Yamanaka, 2006; Zhao et al., 2009).
How PSCs maintain their ability for self-renewal and
pluripotency is a fundamental issue in cell biology. Studies in
recent years have pointed to epigenetic mechanisms that
could control the difference between PSCs and somatic
cells. Compared with differentiated somatic cells, ESCs have
unique features: they have a more “open” conformation of
chromatin structure, including the telomeric region. The
repressive histone modiﬁcations are less prevailing in the
ESC genome, compared to those in differentiated cells
(Hawkins et al., 2010; Wen et al., 2009). Many transcription
factors that control cell fate determination are epigenetically
marked by either active (such as methylated H3K4) or
repressive (like methylated H3K27) histone modiﬁcations.
These bivalent chromatin states provide the plasticity for
maintaining ESC pluripotency and regulating the expression
level of lineage-speciﬁc genes during differentiation (Bern-
stein et al., 2006). For iPSCs, the epigenetic status of suc-
cessfully induced cells is highly similar to the ESCs,
including changes in histone modiﬁcations and DNA meth-
ylation at the gene loci that are required for the maintenance
of pluripotency and lineage speciﬁcation, as well as efﬁcient
activation of the telomerase and elongation of telomeres
(Marion et al., 2009; Takahashi et al., 2007; Takahashi and
Yamanaka, 2006).
In addition, ESCs may also have evolved more stringent
mechanisms to protect genome integrity compared to dif-
ferentiated cells. For example, ESCs harbor much lower
mutation and recombination rate than somatic cells (Cer-
vantes et al., 2002). Moreover, ESCs exhibit hypersensitivity
to DNA damage, efﬁcient DNA repair mechanisms and high
proﬁciency in antioxidant defense, which also help to main-
tain their genome stability (Giachino et al., 2013). The long
and stable telomeres often found in ESCs may be an addi-
tional mechanism to protect chromosomal integrity (Huang
et al., 2011). The telomeres in PSCs, which can be regulated
in a telomerase-dependent or independent (e.g. ALT) fash-
ion, are crucial for PSC biology, which will be discussed in
the following sections.
TELOMERES IN PLURIPOTENT STEM CELLS
While the telomere in somatic cells is usually composed of
heterochromatin, the genome-wide chromatin structure is
relatively open in PSCs. How is the status of telomeric
chromatin in PSCs? Recent studies have shown that PSCs
contain relatively “open” telomeric chromatin that would
switch to become more repressive during differentiation
(Azuara et al., 2006; Bernstein et al., 2006; Meshorer et al.,
2006). Therefore, the telomeric chromatin of PSCs is likely in
a unique and dynamic state that can undergo remodeling
during differentiation (Marion et al., 2009; Wong et al., 2009).
One of the common characteristics of ESCs and iPSCs is
the expression of transcription factors Oct4, Sox2, and Na-
nog, as well as constitutively high telomerase activity. PSCs
can use the telomerase pathway to elongate their telomeres
(Blasco, 2007; Hiyama and Hiyama, 2007). The in vivo study
of adult stem cells indicated that adequate telomere length is
a prerequisite for the functionality of stem cells (Flores et al.,
2008).
Dynamic telomere status is not restricted to the aging
process, but is also found during embryo development and
PSC derivation. At the preimplantation embryo stage, telo-
meres are effectively elongated by ALT-like mechanism from
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totipotent zygote to blastocyst and then telomerase is used
to maintain telomere length during ontogenesis in adult stem
cells (Liu et al., 2007) (Fig. 1). Surprisingly, ICM cells in the
blastocyst have different telomere length compared to ESCs
—telomeres extend continuously during murine ESC deri-
vation process. There may be multiple non-mutually exclu-
sive mechanisms contributing to ESC telomere elongation:
one is that both H3K9me3 and H4K20me3 heterochromatic
marks decrease at telomeres; second is high-level expres-
sion of TRF1 that facilitates proﬁcient capping of the newly
synthesized telomeres. These two factors ensured telome-
rase dependent elongating of the telomeres. More interest-
ingly, an ALT-like mechanism is also activated during this
process to rapidly elongate the telomeres, wherein Zscan4 is
involved to maintain genomic stability, (Varela et al., 2011;
Zalzman et al., 2010). Similarly, the study of human ESCs
demonstrated that telomeres were elongated during early
expansion in vitro and then reached to a relatively stable
level in a telomerase-dependent way (Zeng et al., 2013). For
self-renewal and developmental pluripotency, the ESC telo-
mere state is tightly associated with its function. ESCs
with short telomeres show reduced pluripotency as revealed
by teratoma formation and chimera production in vivo
(Huang et al., 2011). In Tert-/- ESCs, critically short telo-
meres induced de novo methyltransferase Dnmt3a2/3b
downregulation, genome-wide DNA hypomethylation, and
altered H3K27me3 enrichment at Nanog and Gata6 pro-
moters as well as at loci distal to telomeres. These epige-
netic changes in turn affect the stable differentiation ability of
ESCs in vitro (Pucci et al., 2013).
During initial iPSC studies, researchers could easily and
effectively obtain iPSCs by introducing the four Yamanaka
factors into somatic cells. Most of these cell lines showed
typical ESC-like colony shape, speciﬁc molecular markers
such as Oct4, Nanog and Sox2, and positive alkaline
phosphatase activity. However, most of these lines could not
produce iPSC-mice by tetraploid complementation except
chimeric mice, indicating that they were not entirely plurip-
otent. A recent report found that murine ESCs/iPSCs with
short telomeres could not produce ESC/iPSC mice directly
and the efﬁciency of teratoma formation and chimera pro-
duction decreased signiﬁcantly (Huang et al., 2011). Also the
porcine iPSC studies found that telomere length is related to
the efﬁciency of teratoma formation and ALT mechanism is
also found in porcine iPSCs (Ji et al., 2013). Although with
some controversy, telomeres can be elongated after somatic
cell nuclear transfer (SCNT) process in many species (Jiang
et al., 2004; Lanza et al., 2000; Shiels et al., 1999; Sparman
et al., 2009). The Blasco group also observed extension of
telomeres during iPSC derivation and passage (Marion
et al., 2009) (Fig. 1). Recently, the comparison of the differ-
ences between the SCNT-mediated and iPSC-based
reprogramming of Terc-/- cells found that SCNT is superior to
iPSC mediated reprogramming in donor cells with telomere
and mitochondria dysfunction, providing an application
insight for reprogramming strategy optimization. (Le et al.,
2014). Furthermore, ectopic expression of factors, which
could protect telomeres such as Zscan4, can increase
induction efﬁciency and pluripotency of iPSCs remarkably
(Jiang et al., 2013). These lines of evidence demonstrate
that telomere elongation and functional reconstruction is
very important for iPSCs to acquire true pluripotency. In fact,
the telomeres of iPSCs have been shown to be remodeled to
features similar to ESCs by both telomerase-dependent and
possible ALT pathway, in both mouse and human (Marion
et al., 2009; Wang et al., 2012; Yehezkel et al., 2011) (Fig. 1).
On the other hand, telomere dysfunction can also impact
cell metabolism through affecting mitochondrial function.
Progressive telomere shortening limits the replication
capacity of dividing cells such as stem cells (Cong et al.,
2002), and induces p53 to repress PGC-1α and PGC-1β,
thereby linking telomeres to mitochondrial biology, oxidative
defense, and metabolism (Sahin et al., 2011). One of the
core telomeric proteins TIN2 was recently shown to localize
to mitochondria, and play an important role in mitochondrial
function regulation. TIN2 appears to negatively modulate
ATP production by limiting efﬁcient electron transport and
decreasing mitochondrial membrane potential (Chen et al.,
2012). Whether mutations of TIN2 would affect the pluripo-
tency of PSCs and the efﬁciency of iPSCs reprogramming in











Figure 1. Telomere length increases during preimplantation
embryo development and PSCs derivation process. At the
embryo stage, telomeres are effectively elongated by a possible
alternative lengthening of telomeres (ALT) pathway from zygote
to blastocyst. However, during early expansion, ESCs obtained
from the inner cell mass (ICM) in vitro continuously elongate
their telomeres to a relatively stable level in a telomerase-
dependent way, and ALT pathway could not be excluded in this
process. Similarly, both telomerase-dependent and independent
mechanism may coexist in the iPSCs reprogramming process.
In summary, the PSCs, including ESCs and iPSCs, need to
elongate their telomeres during the derivation process to
stabilize their genomic DNA and keep their self-renewal and
pluripotency status.
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Tin2-related dyskeratosis congenital (DC) disease models
need further investigation.
Although the mechanism of telomere regulation in the
PSCs remains unclear, the following key modulators of
ESCs/iPSCs telomere maintenance have been found so far
which has expanded our understanding in this ﬁeld.
TELOMERASE IN PLURIPOTENT STEM CELLS
The status of the telomerase is crucial for pluripotency of
adult stem cells and tissue function. Terc-/- mice with null
telomerase activity are viable for only six generations. These
mice exhibit premature aging phenotypes such as gray hair,
kyphosis, smaller body size and shorter life-span. Con-
versely, in Tert-overexpressing transgenic mice, telomerase
reactivation can reverse tissue degeneration in hair follicles,
testes, intestinal crypts and brain in aged telomerase-deﬁ-
cient mice (Flores et al., 2005; Jaskelioff et al., 2011).
Surprisingly, ESCs can be derived from Terc+/- and Terc-/-
mice as efﬁciently as wild type ESCs, indicating that the
telomerase per se is not required for the establishment of
ESC lines. The haplosufﬁcient Terc+/- ESCs had signiﬁcantly
reduced ESC mice production efﬁciency compared with wild
type ESCs. G1 Terc-/- ESCs, derived from ﬁrst generation
Terc-/- mice with normal karyotypes and shorter telomeres,
could not produce any ESC mice by 8-cell embryos injecton,
even though G1 Terc-/- ESCs could form teratomas as efﬁ-
ciently as Terc+/- and wild type ESCs. The ESCs from G4
Terc-/- mice display aneuploidy and chromosomal abnor-
malities and could not produce any chimeras (Huang et al.,
2011).
Overexpression of telomerase in mouse and human ESCs
appeared to improve their self-renewal, colony-formation
capacity, resistance to apoptosis and proliferation rate. The
Tert-overexpressing human ESCs are able to form teratomas
composed of three germ layers in vivo, but their ability to dif-
ferentiate into all primitive and embryonic lineages in vitrowas
suppressed (Armstrong et al., 2005; Yang et al., 2008). In
summary, it appears that regulating telomerase activity
appropriately in ESCs is critically important for maintaining
ESC pluripotency and modulating their differentiation.
Other lines of evidence come from the telomerase-asso-
ciated diseases. DC is a rare progressive congenital disorder
with characteristics of high rates of bone marrow failure,
pulmonary ﬁbrosis, oral leukoplakia, nail dystrophy, abnor-
mal skin pigmentation, etc. It is mainly caused by mutations
in genes encoding the telomerase or telomerase-associated
proteins such as DKC1, TERT, TERC, TCAB1 and RTEL1
(Ballew et al., 2013; Bessler et al., 2010; Walne and Dokal,
2009). These DC patients have very short telomeres in their
peripheral blood lymphocytes (Alter et al., 2007). iPSC
studies using ﬁbroblasts from DC patients have shed light on
the interplay between the telomerase and pluripotency
establishment. Reprogrammed iPSCs from Terc destabilized
DC patients could overcome the critical limitation in Terc
levels to restore telomere maintenance and acquire self-
renewal capability (Agarwal et al., 2010). However, iPSCs
from different types of DC patients retain the characteristic
disease defects, and display telomere maintenance defects
that correlate with their corresponding clinical severity
(Batista et al., 2011). In most cases, both mutant and wild
type iPSCs could upregulate Tert and Terc expression levels
compared with parental somatic cells, but mutant iPSCs
usually elongated telomeres at a lower rate compared to
their wild type counterparts. Defective telomere elongation
appears to have a deﬁnitive impact on the true pluripotency
and differentiation abilities of iPSCs (Winkler et al., 2013).
During either ESCs establishment or iPSCs generation,
the mechanism for elongating telomeres seems to be not
conﬁned to the telomerase pathway. When Terc-deleted
ESCs went through crisis after multiple passages, survived
ESCs were found to use ALT pathway to maintain telomeres
(Niida et al., 2000). Moreover, although telomerase reacti-
vation is necessary for reprogramming, ALT-dependent
mechanism is also involved in reprogramming, in a non-
sufﬁcient way (Wang et al., 2012). These results underline
the importance of both telomerase-dependent and inde-
pendent pathways in the regulation of telomeres in PSCs
(Fig. 1).
ALTERNATIVE LENGTHENING OF TELOMERES (ALT)
PATHWAY IN PLURIPOTENT STEM CELLS
While 85%–90% of human cancers extend telomeres
through the upregulation of telomerase activity, 10%–15% of
cancers use the ALT pathway, a process that appears
dependent on homologous recombination (Bryan et al.,
1997; Shay and Bacchetti, 1997). Usually, the two telomere
maintenance mechanisms appear mutually exclusive for
most cells. Mutations of DAXX, ATRX and H3.3 have also
been found to be associated with telomerase-negative
human cancer cells that undergo ALT (Schwartzentruber
et al., 2012). However, ALT and telomerase pathways may
coexist in PSCs, which was supported by the evidence that
telomerase reactivation is accompanied by ALT during
reprogramming and ALT-related H3.3/ATRX colocalize with
telomere within the PML bodies in ESCs (Chang et al., 2013;
Wang et al., 2012).
The histone H3 variant H3.3 was originally thought to be
commonly associated with active chromatin. However,
recent data have revealed that this particular variant can
accumulate on silent loci in heterochromatin, indicating its
possible dual roles in transcriptional regulation (Goldberg
et al., 2010). Interestingly, it was found that H3.3 could
localize to the telomeres in mouse ESCs and embryonic
germ cells, but not in non-pluripotent cells. H3.3 levels
decrease during ESCs differentiation while the heterochro-
matin repressive markers H4K20me3 and H3K9me3
increase in this process. Meanwhile, depletion of H3.3 could
induce dysregulation of telomeres, providing evidence for a
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role of H3.3 in the regulation of telomere chromatin integrity
in ESCs (Wong et al., 2009).
H3.3 can be found in two separate complexes, associat-
ing with either histone deposition factor HIRA or histone
chaperone DAXX. The HIRA complex can deposit H3.3 at
transcribed genes, whereas DAXX and ATRX together with
H3.3 assemble at pericentric heterochromatin and telo-
meres. Strikingly, ATRX and DAXX associate with H3.3 in a
HIRA-independent manner in ESCs, which may explain why
H3.3 has dual roles at both active and repressed genes
(Goldberg et al., 2010). ATRX, short for alpha thalassemia/
mental retardation syndrome X-linked gene, belongs to the
SWI2/SNF2 family of chromatin remodeling proteins. In
cooperation with H3.3 and HP1alpha, ATRX can modulate
telomere chromatin status. ATRX knockdown led to
increased DNA damage at the telomeres in ESCs, but not in
cells such as NIH3T3, indicating a speciﬁc role for ATRX in
ensuring the integrity of ESC telomere chromatin (Wong
et al., 2010b). DAXX or death associated protein is a histone
chaperone required for the deposition of H3.3 at telomeres in
the context of the ATRX-DAXX complex (Drane et al., 2010;
Lewis et al., 2010). Mutations in the ATRX/DAXX complex
and histone H3.3 were found to correlate with features of
ALT in many cancers (Heaphy et al., 2011; Schwartzentruber
et al., 2012). A comprehensive analysis of several ALT cell
lines has indicated that loss or mutations of ATRX are hall-
marks of ALT cell lines. Additionally, genome instability and
altered double-strand break (DSB) repair are also correlated
with ALT (Lovejoy et al., 2012). Whether the ATRX/DAXX
complex contributes to telomere regulation through the ALT
pathway in ESCs needs further investigation.
In ESCs, H3.3, DAXX and ATRX can localize to the
promyelocytic leukemia nuclear bodies (PML-NBs) and form
ALT-associated PML-NBs (APBs), one of the hallmarks of
ALT cells (Chang et al., 2013). Marked by PML and SP100,
PML-NBs are subnuclear compartments in eukaryotic cells
enriched in regulatory proteins that can modulate multiple
cellular processes including gene transcription, tumor sup-
pression, as well as DNA replication and repair (Bernardi
and Pandolﬁ, 2007). The assembly of PML-NBs is correlated
with the pluripotent state of mouse ESCs, suggesting the
PML-NBs serve as important platforms for the study of
telomeric chromatin integrity in ESCs (Chang et al., 2013).
Future studies should focus on novel factors in the PML-NBs
that regulate ESC telomeres and more details should be
demonstrated to unmask the exact mechanism and function
of the ALT pathway in PSCs.
TELOMERE-ASSOCIATED REGULATORS IN
PLURIPOTENT STEM CELLS
As mentioned above, the epigenetic state of telomere chro-
matin may affect telomere length in PSCs. Several reports
support the notion that multiple chromatin modulators may
participate in the regulation of telomere structure and length.
SUV39H1 and SUV39H2, for example, are two histone
methyltransferases required for the enrichment of trimethy-
lated H3K9 on constitutive heterochromatin including both
centromeres and telomeres. Suv39h1 and Suv39h2 double
knockout led to loss of heterochromatic features and
abnormal telomere elongation in murine ESCs and porcine
embryonic stem like cells, respectively (Dang-Nguyen et al.,
2013; Garcia-Cao et al., 2004). Similarly, SUV4-20H1 and
SUV4-20H2 are histone methyltransferases responsible for
H4K20me3 level maintenance. Simultaneous loss of Suv4-
20h1 and Suv4-20h2 resulted in a considerable elongation of
telomeres (Benetti et al., 2007b). Recently, it has also been
found that abrogation of Suv4-20h decreases the hetero-
chromatic mark H4K20me3 at telomeric regions and facili-
tates telomere replenish during reprogramming (Marion
et al., 2011). Consistently, relatively low density of H3K9me3
and H4K20me3 was observed during reprogramming as well
as in ESCs (Marion et al., 2009). This “relaxed” telomeric
chromatin state may facilitate the access of telomerase to
telomeres in PSCs and thus modulate telomere length.
DNA hypermethylation is another epigenetic feature at
subtelomeric regions. The loss of DNA methyltransferases
Dnmt1 or Dnmt3a/Dnmt3b in ESCs, which led to hypome-
thylated subtelomeric chromatin, caused dramatic telomere
elongation by homologous recombination, and phenotypes
similar to ALT cells, including increased T-SCE, APB for-
mation and telomere heterogeneity. It should be noted that a
possible role for the telomerase or other as yet unidentiﬁed
regulators cannot be excluded in this process (Gonzalo
et al., 2006).
Given the importance of telomere maintenance in PSCs,
the factors that can regulate telomerase expression,
recruitment and activity are also expected to play a signiﬁ-
cant part in PSCs. For example, the TPP1-POT1 heterodimer
in the shelterin/telosome complex binds to single-stranded
G-rich telomeric overhangs. TPP1-POT1 association can
enhance POT1-DNA afﬁnity and telomerase recruitment.
TPP1 RNAi in cancer cells caused DNA damage response
at the telomeres and led to telomere dysfunction (Xin et al.,
2007). Indeed, abrogation of TPP1 also abolished telomere
elongation during reprogramming of mouse embryonic
ﬁbroblast (MEF) cells, supporting a role of TPP1 in PSCs
(Tejera et al., 2010). Several transcriptional regulators of the
telomerase in PSCs have also been demonstrated. Hypoxia
inducible factor 1 alpha (HIF1α) was identiﬁed as an
upstream transactivator of Tert in response to hypoxia in
mouse ESCs in a shRNA library screening. HIF1α loss in
ESCs is accompanied by both decreased Tert level and
shortened telomere length, which in turn can be restored by
reintroducing HIFα level in a hypoxic condition (Coussens
et al., 2010). Klf4, one of the four Yamanaka factors (Oct4,
Sox2, Klf4, c-Myc), was found to speciﬁcally and directly
activate the Tert promoter in ESCs. Klf4 knockdown in ESCs
led to reduced Tert expression and ESC differentiation,
whereas overexpression of Tert rescued these phenotypes
REVIEW Yan Huang et al.









(Wong et al., 2010a). In cooperation with Klf4, the classical
multifunctional Wnt/β-catenin signaling pathway can directly
target Tert (Hoffmeyer et al., 2012). These data provide a
direct link between PSC pluripotency and telomerase activity
regulation.
In addition, novel factors have been found to take part in
telomere regulation in PSCs as well. For example, zinc ﬁnger
and SCAN domain containing 4 (Zscan4) is a gene cluster
that contains six members, and expressed speciﬁcally in late
2-cell embryos and ESCs (Falco et al., 2007). It was found
that Zscan4 could elongate telomeres in ESCs by homolo-
gous recombination and form foci on telomeres. Thus
Zscan4 facilitates and maintains genome stability in ESCs in
a telomerase-independent manner (Zalzman et al., 2010).
Further studies in reprogramming demonstrate a consistent
role of Zscan4 in protecting genome stability of PSCs, and
Zscan4 overexpression could rejuvenate the developmental
potency of PSCs in long-term cell culture (Amano et al.,
2013; Jiang et al., 2013). The precise molecular functions of
Zscan4 in the possible ALT pathway in PSCs are still
unclear. The investigation of Zscan4 and other novel factors
should greatly facilitate our understanding of PSC telomere
maintenance mechanism.
PROSPECT
Multiple links between telomere biology and stem cell pluri-
potency have been established. Interestingly, the longest
telomeres appear to exist in adult stem cells where they
become shortened as stem cell function declines. Addition-
ally, higher expression of the shelterin/telosome complex
component TRF1 correlates with higher pluripotency of stem
cells. Consequently, long telomeres and high TRF1 level
have been proposed as stem cell markers (Flores et al.,
2008; Huang et al., 2011; Schneider et al., 2013). Indeed,
telomere status may serve as a benchmark to evaluate the
quality of ESCs and iPSCs, which should have important
implications in the application of PSCs in regenerative
medicine (Fig. 1). Compared with somatic cells, PSCs have
unique combinations of telomere-associated proteins. Elu-
cidating the function of these factors, particularly their spe-
ciﬁc roles in regulating PSC telomeres would be a top
priority. Finally, further understanding of how and why PSCs
maintain their telomeres through both the telomerase and
possible ALT pathway promises great insight into the com-
plicated mechanisms that establish and ensure pluripotency
of stem cells.
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